Phibro Animal Health Corporation reported an 8% increase in net sales, reaching $232.5 million for the first quarter ended September 30, 2022. However, net income decreased by 41% to $3.9 million, and adjusted EBITDA saw a slight decrease of 1% to $22.1 million. The company reiterated its full-year net sales guidance of $960 million to $1 billion and adjusted EBITDA guidance of $113 million to $118 million.
Net sales increased by 8% to $232.5 million, driven by growth in Animal Health and Mineral Nutrition segments.
Net income decreased by 41% to $3.9 million due to higher SG&A expenses and foreign currency losses.
Adjusted EBITDA decreased slightly by 1% to $22.1 million.
Company reiterates full-year net sales and Adjusted EBITDA guidance, but revised guidance for Net income, Diluted EPS, Adjusted net income, Adjusted diluted EPS and Adjusted effective tax rate.
The Company reiterated its guidance for Net sales and Adjusted EBITDA and revised its guidance for Net income, Diluted EPS, Adjusted net income, Adjusted diluted EPS and Adjusted effective tax rate.
Visualization of income flow from segment revenue to net income